CYTOKINETICS INC

(c) In this Item 5(c) of this quarterly report on Form 10-Q, the terms “officers”, “Rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements” have the meanings ascribed to them in Item 408 of Regulation S-K.

The following directors and officers adopted into or terminated a Rule 10b5-1 trading arrangement during the third quarter of 2026:

•

Robert I. Blum. Mr. Blum, our President and Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement on September 11, 2026 that was intended to satisfy the affirmative defense provided for under Rule 10b5-1(c) (the “Blum Plan”). The Blum Plan provides for the sale of up to 240,000 shares of our common stock, subject to certain conditions. The Blum Plan will terminate on theearlier of (x)November 30, 2027 and (y) the sale of all securities that are subject to the plan.

•

Andrew Callos. Mr. Callos, our Executive Vice President, Chief Commercial Officer, adopted a Rule 10b5-1 trading arrangement on August 25, 2026 that was intended to satisfy the affirmative defense provided for under Rule 10b5-1(c) (the “Callos Plan”). The Callos Plan provides for the sale of up to 67,414 shares of our common stock, subject to certain conditions. The Callos Plan will terminate on theearlier of (x)December 1, 2027 and (y) the sale of all securities that are subject to the plan.

•

Robert A. Harrington, M.D. Dr. Harrington, amember of our board of directors, adopted a Rule 10b5-1 trading arrangement on August 31, 2026 that was intended to satisfy the affirmative defense provided for under Rule 10b5-1(c) (the “Harrington Plan”). The Harrington Plan provides for the sale of up to 3,425 shares of our common stock, subject to certain conditions. The Harrington Plan will terminate on theearlierof (x)July 31, 2027 and (y) the sale of all securities that are subject to the plan.

•

John T. Henderson, M.B., Ch.B. Dr. Henderson, the Chairman of our board of directors, adopted a Rule 10b5-1 trading arrangement on August 24, 2026 that was intended to satisfy the affirmative defense provided for under Rule 10b5-1(c) (the “Henderson Plan”). The Henderson Plan provides for the sale of up to 28,064 shares of our common stock, subject to certain conditions. The Henderson Plan will terminate on theearlier of (x)May 18, 2027 and (y) the sale of all securities that are subject to the plan.

•

Sung H. Lee. Mr. Lee, our Executive Vice President, Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement on August 31, 2026 that was intended to satisfy the affirmative defense provided for under Rule 10b5-1(c) (the “Lee Plan”). The Lee Plan provides for the sale of up to 37,991 shares of our common stock, subject to certain conditions. The Lee Plan will terminateon theearlier of (x)December 31, 2027 and (y) the sale of all securities that are subject to the plan.

•

Fady I. Malik, M.D., Ph.D. Dr. Malik, our Executive Vice President, Research and Development, adopted a Rule 10b5-1 trading arrangement on August 24, 2026 that was intended to satisfy the affirmative defense provided for under Rule 10b5-1(c) (the “Malik Plan”). The Malik Plan provides for the sale of up to 144,075 shares of our common stock, subject to certain conditions. The Malik Plan will terminate on theearlier of (x)December 21, 2027 and (y) the sale of all securities that are subject to the plan.

•

B. Lynne Parshall, Esq. Ms. Parshall, amember of our board of directors, adopted a Rule 10b5-1 trading arrangement on August 10, 2026 that was intended to satisfy the affirmative defense provided for under Rule 10b5-1(c) (the “Parshall Plan”). The Parshall Plan provides for the sale of up to 20,000 shares of our common stock, subject to certain conditions. The Parshall Plan will terminate on theearlier of (x)September 3, 2027 and (y) the sale of all securities that are subject to the plan.